These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

339 related articles for article (PubMed ID: 34302745)

  • 1. Dapagliflozin in patients with cardiometabolic risk factors hospitalised with COVID-19 (DARE-19): a randomised, double-blind, placebo-controlled, phase 3 trial.
    Kosiborod MN; Esterline R; Furtado RHM; Oscarsson J; Gasparyan SB; Koch GG; Martinez F; Mukhtar O; Verma S; Chopra V; Buenconsejo J; Langkilde AM; Ambery P; Tang F; Gosch K; Windsor SL; Akin EE; Soares RVP; Moia DDF; Aboudara M; Hoffmann Filho CR; Feitosa ADM; Fonseca A; Garla V; Gordon RA; Javaheri A; Jaeger CP; Leaes PE; Nassif M; Pursley M; Silveira FS; Barroso WKS; Lazcano Soto JR; Nigro Maia L; Berwanger O
    Lancet Diabetes Endocrinol; 2021 Sep; 9(9):586-594. PubMed ID: 34302745
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of dapagliflozin on prevention of major clinical events and recovery in patients with respiratory failure because of COVID-19: Design and rationale for the DARE-19 study.
    Kosiborod M; Berwanger O; Koch GG; Martinez F; Mukhtar O; Verma S; Chopra V; Javaheri A; Ambery P; Gasparyan SB; Buenconsejo J; Sjöström CD; Langkilde AM; Oscarsson J; Esterline R
    Diabetes Obes Metab; 2021 Apr; 23(4):886-896. PubMed ID: 33319454
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of the SGLT2 inhibitor dapagliflozin on proteinuria in non-diabetic patients with chronic kidney disease (DIAMOND): a randomised, double-blind, crossover trial.
    Cherney DZI; Dekkers CCJ; Barbour SJ; Cattran D; Abdul Gafor AH; Greasley PJ; Laverman GD; Lim SK; Di Tanna GL; Reich HN; Vervloet MG; Wong MG; Gansevoort RT; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2020 Jul; 8(7):582-593. PubMed ID: 32559474
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Exenatide once weekly plus dapagliflozin once daily versus exenatide or dapagliflozin alone in patients with type 2 diabetes inadequately controlled with metformin monotherapy (DURATION-8): a 28 week, multicentre, double-blind, phase 3, randomised controlled trial.
    Frías JP; Guja C; Hardy E; Ahmed A; Dong F; Öhman P; Jabbour SA
    Lancet Diabetes Endocrinol; 2016 Dec; 4(12):1004-1016. PubMed ID: 27651331
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial.
    Mosenzon O; Wiviott SD; Cahn A; Rozenberg A; Yanuv I; Goodrich EL; Murphy SA; Heerspink HJL; Zelniker TA; Dwyer JP; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Kato ET; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS; Raz I
    Lancet Diabetes Endocrinol; 2019 Aug; 7(8):606-617. PubMed ID: 31196815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Blood pressure and glycaemic effects of dapagliflozin versus placebo in patients with type 2 diabetes on combination antihypertensive therapy: a randomised, double-blind, placebo-controlled, phase 3 study.
    Weber MA; Mansfield TA; Cain VA; Iqbal N; Parikh S; Ptaszynska A
    Lancet Diabetes Endocrinol; 2016 Mar; 4(3):211-220. PubMed ID: 26620248
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Albuminuria-lowering effect of dapagliflozin alone and in combination with saxagliptin and effect of dapagliflozin and saxagliptin on glycaemic control in patients with type 2 diabetes and chronic kidney disease (DELIGHT): a randomised, double-blind, placebo-controlled trial.
    Pollock C; Stefánsson B; Reyner D; Rossing P; Sjöström CD; Wheeler DC; Langkilde AM; Heerspink HJL
    Lancet Diabetes Endocrinol; 2019 Jun; 7(6):429-441. PubMed ID: 30992195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dapagliflozin and Kidney Outcomes in Hospitalized Patients with COVID-19 Infection: An Analysis of the DARE-19 Randomized Controlled Trial.
    Heerspink HJL; Furtado RHM; Berwanger O; Koch GG; Martinez F; Mukhtar O; Verma S; Gasparyan SB; Tang F; Windsor SL; de Souza-Dantas VC; Del Sueldo M; Frankel R; Javaheri A; Maldonado RA; Morse C; Mota-Gomes M; Shemin D; Silva OL; Tognon AP; Twahirwa M; Buenconsejo J; Esterline R; Oscarsson J; Ambery P; Langkilde AM; Kosiborod MN
    Clin J Am Soc Nephrol; 2022 May; 17(5):643-654. PubMed ID: 35483733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial.
    Bailey CJ; Gross JL; Pieters A; Bastien A; List JF
    Lancet; 2010 Jun; 375(9733):2223-33. PubMed ID: 20609968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial.
    Wheeler DC; Stefánsson BV; Jongs N; Chertow GM; Greene T; Hou FF; McMurray JJV; Correa-Rotter R; Rossing P; Toto RD; Sjöström CD; Langkilde AM; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Jan; 9(1):22-31. PubMed ID: 33338413
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy and safety of dapagliflozin in patients with heart failure with mildly reduced or preserved ejection fraction by baseline glycaemic status (DELIVER): a subgroup analysis from an international, multicentre, double-blind, randomised, placebo-controlled trial.
    Inzucchi SE; Claggett BL; Vaduganathan M; Desai AS; Jhund PS; de Boer RA; Hernandez AF; Kosiborod MN; Lam CSP; Martinez F; Shah SJ; Verma S; Han Y; Kerr Saraiva JF; Bengtsson O; Petersson M; Langkilde AM; McMurray JJV; Solomon SD
    Lancet Diabetes Endocrinol; 2022 Dec; 10(12):869-881. PubMed ID: 36372069
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of dapagliflozin on urinary albumin excretion in patients with chronic kidney disease with and without type 2 diabetes: a prespecified analysis from the DAPA-CKD trial.
    Jongs N; Greene T; Chertow GM; McMurray JJV; Langkilde AM; Correa-Rotter R; Rossing P; Sjöström CD; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL;
    Lancet Diabetes Endocrinol; 2021 Nov; 9(11):755-766. PubMed ID: 34619106
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of dapagliflozin on kidney and cardiovascular outcomes by baseline KDIGO risk categories: a post hoc analysis of the DAPA-CKD trial.
    Waijer SW; Vart P; Cherney DZI; Chertow GM; Jongs N; Langkilde AM; Mann JFE; Mosenzon O; McMurray JJV; Rossing P; Correa-Rotter R; Stefansson BV; Toto RD; Wheeler DC; Heerspink HJL
    Diabetologia; 2022 Jul; 65(7):1085-1097. PubMed ID: 35445820
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial.
    Dandona P; Mathieu C; Phillip M; Hansen L; Griffen SC; Tschöpe D; Thorén F; Xu J; Langkilde AM;
    Lancet Diabetes Endocrinol; 2017 Nov; 5(11):864-876. PubMed ID: 28919061
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of Dapagliflozin on Worsening Heart Failure and Cardiovascular Death in Patients With Heart Failure With and Without Diabetes.
    Petrie MC; Verma S; Docherty KF; Inzucchi SE; Anand I; Belohlávek J; Böhm M; Chiang CE; Chopra VK; de Boer RA; Desai AS; Diez M; Drozdz J; Dukát A; Ge J; Howlett J; Katova T; Kitakaze M; Ljungman CEA; Merkely B; Nicolau JC; O'Meara E; Vinh PN; Schou M; Tereshchenko S; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; Johanson P; Greasley PJ; Boulton D; Bengtsson O; Jhund PS; McMurray JJV
    JAMA; 2020 Apr; 323(14):1353-1368. PubMed ID: 32219386
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effects of dapagliflozin on hospitalisations in people with type 2 diabetes: post-hoc analyses of the DECLARE-TIMI 58 trial.
    Schechter M; Wiviott SD; Raz I; Goodrich EL; Rozenberg A; Yanuv I; Murphy SA; Zelniker TA; Fredriksson M; Johansson PA; Leiter LA; Bhatt DL; McGuire DK; Wilding JPH; Gause-Nilsson IAM; Cahn A; Langkilde AM; Sabatine MS; Mosenzon O
    Lancet Diabetes Endocrinol; 2023 Apr; 11(4):233-241. PubMed ID: 36878239
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
    Wiviott SD; Raz I; Bonaca MP; Mosenzon O; Kato ET; Cahn A; Silverman MG; Zelniker TA; Kuder JF; Murphy SA; Bhatt DL; Leiter LA; McGuire DK; Wilding JPH; Ruff CT; Gause-Nilsson IAM; Fredriksson M; Johansson PA; Langkilde AM; Sabatine MS;
    N Engl J Med; 2019 Jan; 380(4):347-357. PubMed ID: 30415602
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Extrapolating Long-term Event-Free and Overall Survival With Dapagliflozin in Patients With Heart Failure and Reduced Ejection Fraction: An Exploratory Analysis of a Phase 3 Randomized Clinical Trial.
    Docherty KF; Jhund PS; Claggett B; Ferreira JP; Bengtsson O; Inzucchi SE; Køber L; Kosiborod MN; Langkilde AM; Martinez FA; Ponikowski P; Sabatine MS; Sjöstrand M; Solomon SD; McMurray JJV;
    JAMA Cardiol; 2021 Nov; 6(11):1298-1305. PubMed ID: 34319398
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dapagliflozin in Myocardial Infarction without Diabetes or Heart Failure.
    James S; Erlinge D; Storey RF; McGuire DK; de Belder M; Eriksson N; Andersen K; Austin D; Arefalk G; Carrick D; Hofmann R; Hoole SP; Jones DA; Lee K; Tygesen H; Johansson PA; Langkilde AM; Ridderstråle W; Parvaresh Rizi E; Deanfield J; Oldgren J
    NEJM Evid; 2024 Feb; 3(2):EVIDoa2300286. PubMed ID: 38320489
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Exploring the potential of the SGLT2 inhibitor dapagliflozin in type 1 diabetes: a randomized, double-blind, placebo-controlled pilot study.
    Henry RR; Rosenstock J; Edelman S; Mudaliar S; Chalamandaris AG; Kasichayanula S; Bogle A; Iqbal N; List J; Griffen SC
    Diabetes Care; 2015 Mar; 38(3):412-9. PubMed ID: 25271207
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.